Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zabdeno
- Development stage
- Phase 3
- Lead developer
- Janssen Pharmaceutical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad26.ZEBOV (zabdeno) is a monovalent, non-replicating viral vector vaccine developed by Janssen Pharmaceutical (a subsidiary of Johnson & Johnson) for the prevention of Ebola virus disease caused by Zaire ebolavirus. The vaccine utilizes Janssen's proprietary AdVac technology, featuring a recombinant adenovirus serotype 26 (Ad26) vector that expresses the glycoprotein (GP) of the Ebola virus Mayinga strain. It is typically administered as the first dose (prime) in a heterologous two-dose regimen, followed by MVA-BN-Filo (Mvabea) as the second dose (boost) approximately 56 days later. This prime-boost strategy is designed to induce a robust and durable immune response, including both humoral and cellular immunity. Ad26.ZEBOV received marketing authorization from the European Commission in July 2020 and has been prequalified by the World Health Organization for use in individuals aged one year and older.
- Brand names
- Zabdeno
- Other names
- Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoproteinzabdeno
02
Targets
NPC1 (Niemann-Pick C1 protein binding inhibition)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on zabdeno.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zabdeno.